PepSets™ Peptide Libraries ❭

PepSets™ can be supplied with a precise length and offset designed to best suit the user’s assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence to adapt the usage for any experimental purpose.

In recent years, PepSets™ have had tremendous successes in the immunology sector for vaccine and drug development. These versatile molecular tools have further applications in dozens of fields, including epitope mapping and structure-activity studies.  

  • Discover crucial residues with an Alanine Scan Library 
  • Map epitopes with an Overlapping Peptide Library 
  • Narrow down the shortest active sequences with a Truncated Peptide Library

Fast & Reliable

Mimotopes is the founder of peptide libraries. Across the 35 years since its inception, the technology and its userbase have developed side-by-side to make PepSets™ an unrivaled juggernaut in research today.

Hundreds of peptides are synthesized simultaneously with Mimotopes’ exclusive parallel synthesis technology. Thanks to a rapid production cycle, peptide libraries reach their users fast, aiming to never delay critical experiments.

Contact us today for a quote!

Australia

☎ +61 3 9565 1111
✉ australia@mimotopes.com

North and South America

☎ +1 651 603 0909
✉ useast@mimotopes.com
uswest@mimotopes.com

Asia

☎ +61 3 9565 1111
✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547
✉ europe@mimotopes.com

Go to article: Home | Lula’s progress plan for Brazil: A year onGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: XylemGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: phasetwoGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DepthGo to article: Lula’s progress plan for Brazil: A year on Go to article: How sham patents are hurting the pharma industryGo to article: Tracking the opioid lawsuit settlements amidst calls for oversight Go to article: Cell and gene therapy landscape in the USGo to article: Q&A: Cell and gene therapy value assessments need a rework to allow access Go to article: Pharmaceutical discovery through a gravitational lens Go to article: Thematic Take: ESGGo to article: Thematic Take: contentsGo to article: Foreword: A growing sense of urgency in ESG Go to article: ESG 1.0 is over – get ready for ESG 2.0 Go to article: ESG becomes mandatory: how to prepareGo to article: Theme timeline: the past, present and future of ESG Go to article: Net-zero strategies for the pharma sector Go to article: Leading pharma companies and initiatives in the race for net zeroGo to article: GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses Go to article: 38% of companies lack an ESG strategy – GlobalData survey Go to article: Sustainability challenges in rare disease trials remain, but change is happeningGo to article: ESCMID 2024: The infectious consequences of climate change Go to article: Bring your own device: How patients own tech is being used in clinical trialsGo to article: Can pharma overcome generative AI’s bias problem?Go to article: China-US tensions are spilling into the biotech sector Go to article: Japanese patients among least empowered in the developed worldGo to article: World Air Quality Report: what are the health impacts and where is it worst? Go to article: Why has New Zealand U-turned on the world’s first smoking ban?Go to article: Microplastics in placentas: how serious is the problem? Go to article: Deal activity related to ESG in the pharma industry since 2021Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: CytivaGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue